Please enable JavaScript or talk to your local administrator to get JavaScript enabled.
Skip filters
Skip facets
  • 11

  • 10

  • 7

  • 3

  • 2

  • 2

  • 2

  • 2

  • 2

  • 1

Funder Group
Research Organization
FOR (ANZSRC) Category
RCDC Category
Country of Funder
Start Year
Active Year
Similar Projects for


Novel therapeutic approaches, based on drug repurposing, for high risk non muscle invasive bladder cancer driven by patients’ proteomic signatures

Funder: European Commission

Funding period
EUR 163 K
USD 182 K
Funding amount
Bladder Cancer (BC) is the costlier cancer type to manage, characterized by high recurrence and progression rates. Despite recent advancements, current BC therapeutic strategies remain suboptimal, mostly due to the disease molecular heterogeneity. Profiling at the transcriptomics and, very recently, proteomics levels, revealed the existence of a cross-omics conserved molecular signature marking progression from low to high risk non muscle invasive (NMIBC) and eventually muscle invasive disease. ReDrugBC targets to identify drugs, via drug repurposing, able to revert the aggressive molecular signature for NMIBC, hence tackling the disease at an earlier stage and on a more holistic manner. To address this state-of-the-art concept, ReDrugBC is divided into three highly interrelated strategic points: 1) drug identification (among existing compounds) for NMIBC based on the existent tissue molecular profiles analyzed in a multi-layer and multi-omics manner using specialized bioinformatics-drug prediction tools, 2) definition of impact of selected drugs on the functional properties of BC cell lines in vitro and 3) characterization and understanding of the drug impact on a molecular level, via the application of high-throughput proteomics analysis. This research program will be carried out in a research intensive SME-leader in clinical proteomics and multi-dimensional analysis, by a very active and promising young researcher originating from academia, in a multidisciplinary, implementation-oriented manner. Outreach activities include among others links to pharmaceutical companies and regulators to accelerate progress towards (pre-) clinical trials post-ReDrugBC. Collectively, the proposed approach in ReDrugBC paves the way for better treatment of NMIBC via drug selection based on the patient molecular signatures, while offering unique inter-sectorial training on translational research to a highly motivated young female researcher.

USD 34.4 M
Aggregated funding amount
USD 1.0 M
Average funding amount
Project list item
Epigenetic regulators of subtype plasticity in bladder cancer

Bladder Cancer Advocacy Network to John Robert Christin

USD 1,700
2020 - 2020
Project list item
CD40 agonism for the treatment of bladder cancer

National Cancer Institute to CHRISTOPHER STUART GARRIS

USD 64,554
2020 - 2023
Project list item
moleculaR -based, Data -driven drug REpurposing for bladder Cancer

National Research Fund Luxembourg to Schneider Reinhard

2020 -
Project list item
Engineering Smart Solutions for Disorders of the Bladder Urothelium

Engineering and Physical Sciences Research Council

2019 - 2023
Project list item
Geriatric Conditions and Treatment Burden in Older Adults with Non-Muscle-Invasive Bladder Cancer and Their Caregivers

National Institute on Aging to TULLIKA GARG

USD 271,698
2019 - 2021
Project list item
Combatting Bladder Cancer by Inducing Epithelial Turnover

National Cancer Institute to SOMAN N ABRAHAM

USD 372,404
2019 - 2021
Project list item
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)

National Cancer Institute to NOAH M HAHN

USD 1,313,632
2019 - 2024
Project list item
Development of an automated method to capture bladder cancer recurrence and progression for epidemiologic research

National Cancer Institute to ANIKET A KAWATKAR, KIM N DANFORTH

USD 382,751
2019 - 2021
Project list item
Identifying DNA Biomarkers of Bacillus Calmette-Guerin (BCG) Resistance in Non-Muscle-Invasive Bladder Cancer

Canadian Institutes of Health Research to Jack Victor Warren Bacon, Alexander William Wyatt

USD 847
2018 - 2019
Project list item
Urinary microbiota characterization of superficial bladder Cancer patients undergoing BCG immunotherapy

São Paulo Research Foundation to Anamaria Aranha Camargo

2018 - 2022
Project list item
Transurethral En Bloc Versus Standard Resection of Bladder Tumour: A Multi-centre Randomised Controlled Trial (EB-StaR study).

University Grants Committee to TEOH Yuen Chun Jeremy

USD 75,486
2018 - 2020
Project list item
Intra-operative MRI-guided Robotic System for Photothermal Therapy of Bladder Cancer

University Grants Committee to Kwok Ka Wai, TEOH Yuen Chun Jeremy, Vardhanabhuti Varut Vince, Wong Kenneth Kin Yip

USD 81,014
2018 - 2021
Project list item
Deciphering the neoantigen landscape in bladder cancer patients

Swiss National Science Foundation to Laurent Derré, Alexandre Harari, Sylvain Nguyen

USD 642,703
2018 - 2022
Project list item
Ty21a immunotherapy of non-muscle-invasive bladder cancer

Swiss National Science Foundation to Denise Nardelli Haefliger, Sulayman Benmerzoug, Lenka Chalupova, Mathieu Chevalier, Patrice Jichlinski

USD 437,441
2018 - 2021
Project list item
Comparing Two Treatment Options for Recurrent Bladder Cancer

Patient-Centered Outcomes Research Institute

USD 8,541,087
2018 - 2025
Project list item


USD 1,990,950
2017 - 2021
Project list item
Translation of a Clinical Molecular Diagnostic Assay for Bladder Cancer

National Cancer Institute to STEVE GOODISON

USD 1,823,874
2017 - 2022
load more...